Naturally occurring autoantibodies against Aβ oligomers exhibited more beneficial effects in the treatment of mouse model of Alzheimer's disease than intravenous immunoglobulin
- PMID: 26907803
- DOI: 10.1016/j.neuropharm.2016.02.015
Naturally occurring autoantibodies against Aβ oligomers exhibited more beneficial effects in the treatment of mouse model of Alzheimer's disease than intravenous immunoglobulin
Abstract
Alzheimer's disease (AD) is characterized by memory loss, intracellular neurofibrillary tangles, and extracellular plaque deposits composed of β-amyloid (Aβ). Previous reports showed that naturally occurring autoantibodies, such as intravenous immunoglobulin (IVIG), benefited patients with moderate-stage AD who carried an APOE-ε4 allele. However, the mechanism underlying the role of IVIG remains unclear. In this study, we identified naturally occurring autoantibodies against Aβ oligomers (NAbs-Aβo), which were purified by Aβ42 oligomer or Cibacron Blue affinity chromatography from IVIG and termed as Oli-NAbs and Blue-NAbs, respectively. Oli-NAbs and Blue-NAbs recognized Aβ42 oligomers or both Aβ40 and 42 oligomers, differently. Both antibodies inhibited Aβ42 aggregation and attenuated Aβ42-induced cytotoxicity. Compared with vehicles, Oli-NAbs, Blue-NAbs and IVIG significantly improved the memory and cognition, and reduced the soluble and oligomeric Aβ levels in APPswe/PS1dE9 transgenic mice. Further investigation showed that Blue-NAbs at increased doses effectively decreased plaque burden and insoluble Aβ levels, whereas Oli-NAbs significantly declined the microgliosis and astrogliosis, as well as the production of proinflammatory cytokines in vivo. Therefore, high levels of these antibodies against oligomeric Aβ40 or Aβ42 were required, correspondingly, to achieve the optimal effect. NAbs-Aβo could be condensed to a high concentration by affinity chromatography and its isolation from IVIG may not interfere with the normal function of conventional IVIG as its concentration is very low. Thus, the isolated NAbs-Aβo as an extra product of plasma required low cost and the enriched NAbs-Aβo may be more feasible than IVIG for the treatment of AD.
Keywords: Alzheimer's disease; Antibody; Intravenous immunoglobulin; Oligomers; β-amyloid.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Similar articles
-
Naturally occurring autoantibodies against β-Amyloid.Adv Exp Med Biol. 2012;750:91-9. doi: 10.1007/978-1-4614-3461-0_7. Adv Exp Med Biol. 2012. PMID: 22903668 Review.
-
Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease.J Neuroinflammation. 2010 Dec 7;7:90. doi: 10.1186/1742-2094-7-90. J Neuroinflammation. 2010. PMID: 21138577 Free PMC article.
-
Aβ levels in the jugular vein and high molecular weight Aβ oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer's disease.PLoS One. 2017 Apr 10;12(4):e0174630. doi: 10.1371/journal.pone.0174630. eCollection 2017. PLoS One. 2017. PMID: 28394917 Free PMC article. Clinical Trial.
-
Effect of Different Aβ Aggregates as Antigen on the Measure of Naturally Occurring Autoantibodies against Amyloid-β40/42 in IVIG.Curr Alzheimer Res. 2019;16(14):1290-1299. doi: 10.2174/1567205017666200102151731. Curr Alzheimer Res. 2019. PMID: 31894747
-
Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence.Drugs. 2010 Mar 26;70(5):513-28. doi: 10.2165/11533070-000000000-00000. Drugs. 2010. PMID: 20329802 Review.
Cited by
-
Antibody Assay and Anti-Inflammatory Function Evaluation of Therapeutic Potential of Different Intravenous Immunoglobulins for Alzheimer's Disease.Int J Mol Sci. 2023 Mar 14;24(6):5549. doi: 10.3390/ijms24065549. Int J Mol Sci. 2023. PMID: 36982622 Free PMC article.
-
Five-year outcomes after IVIG for mild cognitive impairment due to alzheimer disease.BMC Neurosci. 2021 Aug 6;22(1):49. doi: 10.1186/s12868-021-00651-2. BMC Neurosci. 2021. PMID: 34362303 Free PMC article. Clinical Trial.
-
The Toxicity and Polymorphism of β-Amyloid Oligomers.Int J Mol Sci. 2020 Jun 24;21(12):4477. doi: 10.3390/ijms21124477. Int J Mol Sci. 2020. PMID: 32599696 Free PMC article. Review.
-
Promising Results from Alzheimer's Disease Passive Immunotherapy Support the Development of a Preventive Vaccine.Research (Wash D C). 2019 May 19;2019:5341375. doi: 10.34133/2019/5341375. eCollection 2019. Research (Wash D C). 2019. PMID: 31549066 Free PMC article. Review.
-
Advances in Biosynthesis, Pharmacology, and Pharmacokinetics of Pinocembrin, a Promising Natural Small-Molecule Drug.Molecules. 2019 Jun 24;24(12):2323. doi: 10.3390/molecules24122323. Molecules. 2019. PMID: 31238565 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous